Toward Optimization of the Second Aryl Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies

被引:49
作者
Johnson, Steven M. [1 ,3 ]
Connelly, Stephen [2 ,3 ]
Wilson, Ian A. [2 ,3 ]
Kelly, Jeffery W. [1 ,3 ]
机构
[1] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
关键词
AMYLOID FIBRIL INHIBITORS; SENILE SYSTEMIC AMYLOIDOSIS; PROTEIN-MISFOLDING DISEASES; NATIVE-STATE; KINETIC STABILIZATION; LIVER-TRANSPLANTATION; PRE-ALBUMIN; POTENT; VARIANT; BINDING;
D O I
10.1021/jm801347s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Transthyretin (TTR) amyloidogenesis inhibitors are typically composed of two aromatic rings and a linker. We have previously established optimal structures for one aromatic ring and the linker. Herein, we employ a suboptimal linker and an optimal aryl-X substructure to rank order the desirability of aryl-Z substructures-using a library of 56 N-(3,5-dibromo-4-hydroxyphenyl)benzamides. Coconsideration of amyloid inhibition potency and ex vivo plasma TTR binding selectivity data reveal that 2,6, 2,5, 2, 3,4,5, and 3,5 substituted aryls bearing small substituents generate the most potent and selective inhibitors, in descending order. These benzamides generally lack undesirable thyroid hormone receptor binding and COX-I inhibition activity. Three high-resolution TTR.inhibitor crystal structures (1.31-1.35 angstrom) provide insight into why these inhibitors are potent and selective, enabling future structure-based design of TTR kinetic stabilizers.
引用
收藏
页码:1115 / 1125
页数:11
相关论文
共 74 条
[31]   Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans [J].
Jacobson, DR ;
Pastore, RD ;
Yaghoubian, R ;
Kane, I ;
Gallo, G ;
Buck, FS ;
Buxbaum, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (07) :466-473
[32]   The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis [J].
Jiang, X ;
Buxbaum, JN ;
Kelly, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :14943-14948
[33]   Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses [J].
Johnson, SM ;
Wiseman, RL ;
Sekijima, Y ;
Green, NS ;
Adamski-Werner, SL ;
Kelly, JW .
ACCOUNTS OF CHEMICAL RESEARCH, 2005, 38 (12) :911-921
[34]   Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation [J].
Johnson, SM ;
Petrassi, HM ;
Palaninathan, SK ;
Mohamedmohaideen, NN ;
Purkey, HE ;
Nichols, C ;
Chiang, KP ;
Walkup, T ;
Sacchettini, JC ;
Sharpless, KB ;
Kelly, JW .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) :1576-1587
[35]   Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies [J].
Johnson, Steven M. ;
Connelly, Stephen ;
Wilson, Ian A. ;
Kelly, Jeffery W. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (20) :6348-6358
[36]   Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors [J].
Johnson, Steven M. ;
Connelly, Stephen ;
Wilson, Ian A. ;
Kelly, Jeffery W. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (02) :260-270
[37]  
Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6
[38]  
Klabunde T, 2000, NAT STRUCT BIOL, V7, P312
[39]   The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions [J].
Lashuel, HA ;
Wurth, C ;
Woo, L ;
Kelly, JW .
BIOCHEMISTRY, 1999, 38 (41) :13560-13573
[40]   PROCHECK - A PROGRAM TO CHECK THE STEREOCHEMICAL QUALITY OF PROTEIN STRUCTURES [J].
LASKOWSKI, RA ;
MACARTHUR, MW ;
MOSS, DS ;
THORNTON, JM .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1993, 26 :283-291